<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - AFLIBERCEPT</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>AFLIBERCEPT</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Neovascular (wet) age-related macular degeneration (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2 mg once a month for 3 months, to be injected into the affected eye, then 2 mg every 2 months, review treatment frequency after 12 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Macular oedema secondary to central retinal vein occlusion (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2 mg once a month, to be injected into the affected eye, monitor visual and anatomic outcomes monthly; continue treatment until visual and anatomic outcomes are stable for 3 monthly assessments (discontinue treatment if no improvement in visual and anatomic outcomes after initial 3 injections); if necessary subsequent doses may be given at least 1 month apart.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diabetic macular oedema (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2 mg once a month for 5 months, then maintenance 2 mg every 2 months, to be injected into the affected eye, review treatment frequency after 12 months (discontinue treatment if no improvement in visual and anatomic outcomes).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">In combination with irinotecan, fluorouracil and folinic acid (FOLFIRI) chemotherapy, in metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing regimen</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult local protocol).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor and binds to vascular endothelial growth factors A and B (VEGF-A, VEGF-B) and placental growth factor (PlGF). Aflibercept inhibits the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravitreal</ph> use</h3>
              <p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Caution in severe impairment&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Caution in severe impairment&#8212; no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abdominal pain, aphthous stomatitis, decreased appetite, dehydration, diarrhoea, dysphonia, dyspnoea, fistula, haemorrhage (including nasal, rectal and gastro-intestinal), haemorrhoids, hand-foot syndrome, headache, hypertension, infection, leucopenia, malaise, nasopharyngitis, neutropenia (including febrile neutropenia), oropharyngeal pain, proctalgia, proteinuria, rhinorrhoea, sepsis, skin hyperpigmentation, stomatitis, thrombocytopenia, thromboembolic events (arterial and venous), toothache, urinary tract infection, weight loss, blurred vision, cataract formation, conjunctival haemorrhage, conjunctival hyperaemia, corneal abrasion or oedema, corneal erosion, eye pain, eyelid oedema, foreign body sensation in eye, increased lacrimation, injection-site haemorrhage, injection-site pain, ocular hyperaemia, punctate keratitis, raised intra-ocular pressure, reduced visual acuity, retinal degeneration, retinal pigment epithelium detachment, retinal pigment epithelium tear, vitreous detachment, vitreous floaters, vitreous haemorrhage,
              </p>
              <p>
                <strong>uncommon:</strong> gastro-intestinal perforation, impaired wound healing, nephrotic syndrome, posterior reversible encephalopathy syndrome, thrombotic microangiopathy, anterior chamber flare, blindness, corneal epithelium defect, eyelid irritation, iridocyclitis, iritis, lenticular opacities, retinal detachment, retinal tear, uveitis,
              </p>
              <p>
                <strong>rare:</strong> hypopyon, vitritis,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravitreal</ph> use</h3>
              <p>For further information on administration, consult product literature.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA294</h3>
              <p outputclass="specificity">With <ph outputclass="route">intravitreal</ph> use</p> <p outputclass="title">Aflibercept solution for injection for treating wet age-related macular degeneration (July 2013)</p> <p>Aflibercept solution for injection is recommended as an option for treating wet age-related macular degeneration only if:</p> <ul> <li>it is used in accordance with the recommendations for ranibizumab in NICE TA 155 <b>and</b> </li> <li>the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme</li> </ul><xref format="html" href="http://www.nice.org.uk/TA294">www.nice.org.uk/TA294</xref>
                <a href="http://www.nice.org.uk/TA294" target="_blank">www.nice.org.uk/TA294</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA305</h3>
              <p outputclass="specificity">With <ph outputclass="route">intravitreal</ph> use</p> <p outputclass="title">Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (February 2014)</p> <p>Aflibercept solution for injection is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only if the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.</p><xref format="html" href="http://www.nice.org.uk/TA305">www.nice.org.uk/TA305</xref>
                <a href="http://www.nice.org.uk/TA305" target="_blank">www.nice.org.uk/TA305</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA307</h3>
              <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p> <p outputclass="title">Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)</p> <p>Aflibercept in combination with irinotecan and fluorouracil-based therapy is <b>not</b> recommended within its marketing authorisation for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.</p><xref format="html" href="http://www.nice.org.uk/TA307">www.nice.org.uk/TA307</xref>
                <a href="http://www.nice.org.uk/TA307" target="_blank">www.nice.org.uk/TA307</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intravenous use:</strong>
            febrile neutropenia
          </li>
          <li>
              <strong>With intravenous use:</strong>
            history of cardiovascular disease (may be exacerbated by hypertension)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            increased risk of haemorrhage (including fatal events)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            increased risk of hypertension
          </li>
          <li>
              <strong>With intravenous use:</strong>
            increased risk of thromboembolic events (consult product literature if event occurs)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            may impair wound healing&#8212;withhold treatment for at least 4 weeks before elective surgery and for at least 4 weeks after major surgery, or until wound fully healed
          </li>
          <li>
              <strong>With intravenous use:</strong>
            neutropenic infection
          </li>
          <li>
              <strong>With intravenous use:</strong>
            risk of fistula formation (discontinue if fistula develops)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            risk of neutropenia
          </li>
          <li>
              <strong>With intravenous use:</strong>
            risk of thrombocytopenia
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            active systemic infection
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            diabetic patients with uncontrolled hypertension
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            discontinue treatment if stage 3 or 4 macular holes develop&#8212;consult product literature for full details
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            discontinue treatment in the event of a retinal break&#8212;consult product literature for full details
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            discontinue treatment in the event of rhegmatogenous retinal detachment&#8212;consult product literature for full details
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            patients at risk of retinal pigment epithelial tear
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            poorly controlled glaucoma
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            recent history of myocardial infarction
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            recent history of stroke
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            recent history of transient ischaemic attack
          </li>
        </ul>
        <ul>
          <li>
            <p>Aflibercept is given by intravitreal injection by specialists experienced in the management of this condition. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections&#8212;patients should be advised to report any signs of infection immediately.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravitreal</ph> use</h3>
              <p>Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Exclude pregnancy before treatment.</p><p>Effective contraception required during and for at least 6 months after treatment in men and women.</p><p>Contraceptive advice should be given to men and women before therapy begins (and should cover the duration of contraception required after therapy has ended).</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Monitor blood pressure at initiation and at least fortnightly during treatment (do not initiate treatment if pre-existing hypertension is uncontrolled)&#8212;consult product literature if hypertension develops during treatment.</p><p>Monitor for signs of gastro-intestinal perforation (discontinue if perforation develops).</p><p>Monitor full blood count, including differential count and platelets at baseline and before each treatment cycle.</p><p>Monitor for proteinuria before each treatment administration (consult product literature if symptoms develop).</p><p>Monitor for signs and symptoms of diarrhoea and dehydration, particularly in elderly&#8212;consult product literature if severe diarrhoea occurs.</p><p>Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, altered mental status, nausea, vomiting, headache, or visual disturbance).</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravitreal</ph> use</h3>
              <p>Monitor intra-ocular pressure following injection.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of AFLIBERCEPT</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75911"><a href="../medicinalForm/PHP75911.html" data-target="#PHP75911" data-action="load">Solution for injection</a></div>
            <div id="PHP75917"><a href="../medicinalForm/PHP75917.html" data-target="#PHP75917" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
